
    
      A total of 540 patients with CIU will be enrolled in this pivotal, randomised, multicentre,
      international, double-blind, placebo and active-comparator controlled, parallel study .
      Patients will be selected from both public and private clinical practices. The study
      population includes males and females between 18 and 70 years of age, suffering from CIU for
      at least 6 weeks prior to entry in the study with no identifiable cause.
    
  